Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

10 Nov 2022

Bimekizumab Demonstrated Sustained Clinical Responses to Week 52 in Phase 3 Studies in Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Read More
8 Nov 2022

UCB Reinforces Commitment to Rheumatology with 15 Abstracts including New Late-Breaking Data at ACR Convergence 2022

Read More
13 Oct 2022

UCB announces positive preliminary results for major brivaracetam (Briviact[®]) study in Asia

Read More
27 Sep 2022

FINTEPLA[®▼] (fenfluramine) Approved in Japan for the Treatment of Seizures Associated with Dravet Syndrome

Read More
23 Sep 2022

Disposal of own shares

Read More
22 Sep 2022

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Read More

Stay up-to-date on the latest news and information from UCB